ライフサイエンスコーパス: pouchitis

1 of Crohn's disease, ulcerative colitis, and pouchitis.

2 t the intestinal microbiome of patients with pouchitis.

3 the microbiome and host transcriptome during pouchitis.

4 ission in patients with antibiotic-dependent pouchitis.

5 nd clinical outcome in patients with chronic pouchitis.

6 s open-labeled trial of antibiotic-dependent pouchitis.

7 tiating between irritable pouch syndrome and pouchitis.

8 on complication of this surgery, however, is pouchitis.

9 tis and chronic pouchitis and delay onset of pouchitis.

10 ther CD of the colon, ulcerative colitis, or pouchitis.

11 f quiescent ulcerative colitis and relapsing pouchitis.

12 Symptoms alone do not reliably diagnose pouchitis.

13 host-microbiome regulatory interface during pouchitis.

14 id not meet the PDAI diagnostic criteria for pouchitis.

15 provide long-term benefit for patients with pouchitis.

16 poor function (18 [30%]: 2 early, 16 late), pouchitis (7 [11%]: 2 early, 5 late) and miscellaneous (

17 2 carriage rate compared with those without pouchitis (72% vs. 45%) and Kaplan-Meier survival analys

18 to be at greater risk for the development of pouchitis after IAPT.

19 dication for colectomy and the occurrence of pouchitis after ileal pouch-anal anastomosis formation.

20 1 receptor antagonist gene allele 2 predicts pouchitis after ileal pouch-anal anastomosis in ulcerati

21 s (UC), aggressive Crohn's disease (CD), and pouchitis after restorative proctocolectomy.

22 se relapse of ulcerative colitis and chronic pouchitis and delay onset of pouchitis.

23 own the benefits of a range of probiotics in pouchitis and in ulcerative colitis, although current ev

24 ccus salivarius prevent relapse of recurrent pouchitis and perhaps decrease the initial onset of pouc

25 bowel syndrome, inflammatory bowel disease, pouchitis, and colonic diverticular disease.

26 potentially prevent and treat Crohn disease, pouchitis, and possibly ulcerative colitis, but optimal

27 y, risk factors, diagnosis and management of pouchitis, and pouch surveillance for neoplasia in patie

28 Crohn's disease, ulcerative colitis, and pouchitis are caused by overly aggressive immune respons

29 Crohn's disease, ulcerative colitis, and pouchitis are the result of continuous microbial antigen

30 ch revision and later complications, such as pouchitis, can mandate pouch excision.

31 s had a significantly increased incidence of pouchitis compared with noncarriers (log-rank test, 6.5)

32 be due to inflammatory conditions, including pouchitis, cuffitis, or Crohn's disease or noninflammato

33 ith irritable pouch syndrome from those with pouchitis, cuffitis, or Crohn's disease with a sensitivi

34 Eight patients with chronic pouchitis (current PDAI >/=7) were treated with FMT via

35 25% of patients with symptoms suggestive of pouchitis did not meet the PDAI diagnostic criteria for

36 histology were assessed in 46 patients using Pouchitis Disease Activity Index (PDAI).

37 doscopy with biopsy, with calculation of the pouchitis disease activity index in a prospective cross-

38 Pouchitis Disease Activity Index symptom scores were ass

39 phic and disease activity data (based on the Pouchitis Disease Activity Index) and measured levels of

40 ch component score to the total PDAI for the pouchitis group.

41 Patients with pouchitis had a higher allele 2 carriage rate compared w

42 Patients with pouchitis had significantly higher mean total PDAI score

43 ive colitis, the treatment and prevention of pouchitis has become the one established indication for

44 's disease, ulcerative colitis, obesity, and pouchitis have been correlated with large-scale imbalanc

45 Numerous risk factors for the development of pouchitis have been identified.

46 The cumulative probability of pouchitis increased from 28% at 5 years to 38% at 10 yea

47 Pouchitis is a common long-term complication in patients

48 Pouchitis is common after ileal pouch-anal anastomosis (

49 Pouchitis is the most common long-term complication of i

50 Pouchitis is the most frequent complication of transanal

51 Excluding pouchitis, late complications were experienced by 29.1%

52 Pouchitis often is diagnosed based on symptoms alone.

53 results suggest that FMT/bacteriotherapy for pouchitis patients requires further optimisation.

54 Patients were classified as either having pouchitis (PDAI score > or =7; N = 22) or as not having

55 PDAI score > or =7; N = 22) or as not having pouchitis (PDAI score <7; N = 24).

56 Adult patients with antibiotic-dependent pouchitis received a 2-week course of various antibiotic

57 Therapy for acute pouchitis remains a short course of antibiotics.

58 s often develop antibiotic-dependent form of pouchitis requiring long-term antibiotic therapy for rem

59 Risk factors for the development of pouchitis should be discussed with patients.

60 For chronic pouchitis, studies found success with rifaximin, tinidaz

61 omise for physiologic, nontoxic treatment of pouchitis, ulcerative colitis, and acute infectious diar

62 ecalibacterium were reduced in patients with pouchitis vs controls; there was a negative correlation

63 le, and ciprofloxacin as optimal therapy for pouchitis, when preventive therapy with probiotics is no

64 olated ileal disease), perianal fistulae and pouchitis, whereas selected probiotic preparations preve

65 inflammation, particularly Crohn disease and pouchitis, whereas viral, bacterial, fungal, and protozo

66 anagement of postoperative complications and pouchitis will also be discussed.